Zealand Pharma announced positive topline results from the multiple ascending dose part of its Phase 1 trial for ZP9830, a novel Kv1.3 ion channel blocker targeting autoimmune diseases. The drug was well tolerated with no serious adverse events in 32 healthy participants over four weeks. These results support ongoing development, including a Phase 1b trial in plaque psoriasis and a planned Phase 2 trial for another autoimmune condition in early 2027. This progress marks a key step toward new immunological treatments for autoimmune and inflammatory diseases.
Zealand Pharma's Phase 1 trial update is presented here with Pluang's Health sector market data as of Oct 19, 2026 12:01 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 81 rose and 66 fell today. Notable movers include IDXX at USD 560.36 with a 5.93% increase, COO at USD 57.94 up 5.58%, and LFST at USD 11.74 down 6.23%.
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Hayati®, a UK-based technology and vaping brand, partnered with elrow at the Edinburgh Festival to launch the "TURN UP WITH HAYATI®" activation. This collaboration featured a dedicated space with interactive activities, special festival edition produ...
Wormhole (W) has fallen about 10% recently, driven mainly by large investors (whales) selling on OKX, while Binance whales are accumulating. The Funding Rate shows reduced bearish pressure, improving from -0.0484% to -0.0083%, indicating a gradual bu...
The XRP Ledger is set to implement a bug-fix patch on October 23 that addresses issues in Ripple's proposed uncollateralized lending system, which remains inactive due to insufficient validator votes. The patch, requiring 29 validator approvals, also...
